How to face chronic liver disease: The sinusoidal perspective

Frontiers in Medicine

Volumn 4, Issue FEB, 2017, Pages

  Fernández Iglesias, Anabel ^a   Gracia Sancho, Jordi ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Cirrhosis; Hepatic stellate cells; HSC; Liver sinusoidal endothelial cells; LSEC

Indexed keywords

EID: 85052971151     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2017.00007     Document Type: Review

References (80)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 380(9859):2095-0128. doi:10.1016/S0140-6736(12)61728-0
2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet (2008) 371(9615):838-51. doi:10.1016/S0140-6736(08)60383-9
3. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet (2014) 383(9930):1749-61. doi:10.1016/S0140-6736(14)60121-5
4. de Franchis R, Faculty BV. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol (2015) 63:743-52. doi:10.1016/j.jhep.2015.05.022
5. Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. J Hepatol (2015) 62:S121-30. doi:10.1016/j.jhep.2015.01.003
6. Gracia-Sancho J, Maeso-Díaz R, Fernández-Iglesias A, Navarro-Zornoza M, Bosch J. New cellular and molecular targets for the treatment of portal hypertension. Hepatol Int (2015) 9(2):183-91. doi:10.1007/s12072-015-9613-5
7. Gracia-Sancho J, Laleman W. Mechanisms of portal hypertension: bench to bedside. Clin Liver Dis (2016) 8(6):160-6. doi:10.1002/cld.604
8. Marrone G, Shah VH, Gracia-Sancho J. Sinusoidal communication in liver fibrosis and regeneration. J Hepatol (2016) 65(3):608-17. doi:10.1016/j.jhep.2016.04.018
9. Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol (2010) 53:976-80. doi:10.1016/j.jhep.2010.07.004
10. Zipprich A, Loureiro-Silva MR, D'Silva I, Groszmann RJ. The role of hepatic arterial flow on portal venous and hepatic venous wedged pressure in the isolated perfused CCl4-cirrhotic liver. Am J Physiol Gastrointest Liver Physiol (2008) 295(1):G197-202. doi:10.1152/ajpgi.00190.2007
11. Reynaert H, Urbain D, Geerts A. Regulation of sinusoidal perfusion in portal hypertension. Anat Rec (Hoboken) (2008) 291(6):693-8. doi:10.1002/ar.20669
12. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta (2006) 364(1-2):33-60. doi:10.1016/j.cca.2005.06.014
13. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut (2008) 57(9):1300-14. doi:10.1136/gut.2007.144584
14. Gotzmann J, Fischer ANM, Zojer M, Mikula M, Proell V, Huber H, et al. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene (2006) 25(22):3170-85. doi:10.1038/sj.onc.1209083
15. Liu C, Li J, Xiang X, Guo L, Tu K, Liu Q, et al. PDGF receptor-a promotes TGF-β signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-β receptors. Am J Physiol Gastrointest Liver Physiol (2014) 307(7):G749-59. doi:10.1152/ajpgi.00138.2014
16. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 134:1655-69. doi:10.1053/j.gastro.2008.03.003
17. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med (2006) 10:76-99. doi:10.1111/j.1582-4934.2006.tb00292.x
18. Svegliati-Baroni G, Inagaki Y, Rincon-Sanchez AR, Else C, Saccomanno S, Benedetti A, et al. Early response of alpha2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-beta independent. Hepatology (2005) 42:343-52. doi:10.1002/hep.20798
19. Choi SS, Omenetti A, Witek RP, Moylan CA, Syn W-K, Jung Y, et al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol (2009) 297(6):G1093-106. doi:10.1152/ajpgi.00292.2009
20. Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One (2011) 6(9):e23943. doi:10.1371/journal.pone.0023943
21. Yang L, Wang Y, Mao H, Fleig S, Omenetti A, Brown KD, et al. Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol (2008) 48(1):98-106. doi:10.1016/j.jhep.2007.07.032
22. Gorojankina T. Hedgehog signaling pathway: a novel model and molecular mechanisms of signal transduction. Cell Mol Life Sci (2016) 73(7):1317-32. doi:10.1007/s00018-015-2127-4
23. Omenetti A, Choi S, Michelotti G, Diehl AM. Hedgehog signaling in the liver. J Hepatol (2011) 54:366-73. doi:10.1016/j.jhep.2010.10.003
24. Hyun J, Jung Y. MicroRNAs in liver fibrosis: focusing on the interaction with hedgehog signaling. World J Gastroenterol (2016) 22(29):6652-62. doi:10.3748/wjg.v22.i29.6652
25. Choi SS, Omenetti A, Syn WK, Diehl AM. The role of Hedgehog signaling in fibrogenic liver repair. Int J Biochem Cell Biol (2011) 43:238-44. doi:10.1016/j.biocel.2010.10.015
26. Merchant JL, Saqui-Salces M. Inhibition of Hedgehog signaling in the gastrointestinal tract: targeting the cancer microenvironment. Cancer Treat Rev (2014) 40(1):12-21. doi:10.1016/j.ctrv.2013.08.003
27. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology (2008) 135(5):1729-38. doi:10.1053/j.gastro.2008.07.065
28. Sugimura R, He XC, Venkatraman A, Arai F, Box A, Semerad C, et al. Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. Cell (2012) 150(2):351-65. doi:10.1016/j.cell.2012.05.041
29. Kordes C, Sawitza I, Häussinger D. Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem Biophys Res Commun (2008) 367(1):116-23. doi:10.1016/j.bbrc.2007.12.085
30. Monga SP. β-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology (2015) 148(7):1294-310. doi:10.1053/j.gastro.2015.02.056
31. Wiest R. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology (2002) 35(2):478-91. doi:10.1053/jhep.2002.31432
32. Gracia-Sancho J, Russo L, Garcia-Caldero H, Garcia-Pagan JC, Garcia-Cardena G, Bosch J. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut (2011) 60:517-24. doi:10.1136/gut.2010.220913
33. Saile B, Matthes N, El Armouche H, Neubauer K, Ramadori G. The bcl, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. Eur J Cell Biol (2001) 80(8):554-61. doi:10.1078/0171-9335-00182
34. Graupera M, March S, Engel P, Rodés J, Bosch J, García-Pagán J-C. Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol (2005) 288(4):G763-70. doi:10.1152/ajpgi.00300.2004
35. Gracia-Sancho J, Laviña B, Rodríguez-Vilarrupla A, García-Calderó H, Fernández M, Bosch J, et al. Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology (2008) 47(4):1248-56. doi:10.1002/hep.22166
36. Xie G, Choi SS, Syn WK, Michelotti GA, Swiderska M, Karaca G, et al. Hedgehog signalling regulates liver sinusoidal endothelial cell capillarisation. Gut (2012) 62(2):299-309. doi:10.1136/gutjnl-2011-301494
37. Witek RP, Yang L, Liu R, Jung Y, Omenetti A, Syn WK, et al. Liver cell-derived microparticles activate Hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology (2009) 136(1):320.e-30.e. doi:10.1053/j.gastro.2008.09.066
38. Coultas L, Nieuwenhuis E, Anderson GA, Cabezas J, Nagy A, Henkelman RM, et al. Hedgehog regulates distinct vascular patterning events through VEGF-dependent and-independent mechanisms. Blood (2010) 116(4):653-60. doi:10.1182/blood-2009-12-256644
39. DeLeve LD, Wang X, Hu L, McCuskey MK, McCuskey RS. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol (2004) 287(4):G757-63. doi:10.1152/ajpgi.00017.2004
40. Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol (2016) 13(3):316-27. doi:10.1038/cmi.2015.104
41. Mehta G, Gustot T, Mookerjee RP, Garcia-Pagan JC, Fallon MB, Shah VH, et al. Inflammation and portal hypertension-the undiscovered country. J Hepatol (2014) 61:155-63. doi:10.1016/j.jhep.2014.03.014
42. Chakraborty JB, Mann DA. NF-kB signalling: embracing complexity to achieve translation. J Hepatol (2010) 52(2):285-91. doi:10.1016/j.jhep.2009.10.030 Elsevier
43. Luedde T, Schwabe RF. NF-KB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2011) 8(2):108-18. doi:10.1038/nrgastro.2010.213
44. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut (2012) 61(3):416-26. doi:10.1136/gutjnl-2011-300304
45. Zimmermann HW, Trautwein C, Tacke F. Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol (2012) 3:56. doi:10.3389/fphys.2012.00056
46. Berres M-L, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest (2010) 120(11):4129-40. doi:10.1172/JCI41732
47. Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE, Luedde T, et al. The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology (2010) 52(5):1769-82. doi:10.1002/hep.23894
48. Steib CJ, Gerbes AL, Bystron M, Op den Winkel M, Härtl J, Roggel F, et al. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). J Hepatol (2007) 47(2):228-38. doi:10.1016/j.jhep.2007.03.019
49. Titos E, Claria J, Planaguma A, Lopez-Parra M, Gonzalez-Periz A, Gaya J, et al. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells 17. J Leukoc Biol (2005) 78(4):871-8. doi:10.1189/jlb.1204747
50. Shiffman ML, Sterling RK, Contos M, Hubbard S, Long A, Luketic VA, et al. Long term changes in liver histology following treatment of chronic hepatitis C virus. Ann Hepatol (2014) 13(4):340-9
51. Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int (2016). doi:10.1111/liv.13256
52. Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MDA, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology (2004) 126(7):1795-808. doi:10.1053/j.gastro.2004.03.009
53. Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. Expert Opin Emerg Drugs (2016) 21(2):167-81. doi:10.1080/14728214.2016.1184647
54. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 46(1):242-53. doi:10.1002/hep.21673
55. Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol (2010) 53(4):702-12. doi:10.1016/j.jhep.2010.04.025
56. Trebicka J, Schierwagen R. Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. Gut (2015) 64:1349-50. doi:10.1136/gutjnl-2014-308800
57. Marrone G, Russo L, Rosado E, Hide D, García-Cardeña G, García-Pagán JC, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol (2013) 58(1):98-103. doi:10.1016/j.jhep.2012.08.026
58. Marrone G, Maeso-Diaz R, Garcia-Cardena G, Abraldes JG, Garcia-Pagan JC, Bosch J, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut (2014) 64(9):1434-43. doi:10.1136/gutjnl-2014-308338
59. Maeso-Diaz R, Ortega-Ribera M, Fernandez-Iglesias A, Muñoz L, Vila S, Albillos A, et al. Hepatic microcirculatory phenotype in aging: mildly dysfunctional in health but markedly deteriorated in chronic liver injury. Hepatology (2016) 64(S1):811-1050. doi:10.1002/hep.28800
60. Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology (2009) 136(5):1651-8. doi:10.1053/j.gastro.2009.01.043
61. Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology (2016) 150(5):1160.e-70.e. doi:10.1053/j.gastro.2016.01.004
62. Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology (2016) 150(2):430.e-40.e. doi:10.1053/j.gastro.2015.10.007
63. Gracia-Sancho J, Maeso-Díaz R, Bosch J. Pathophysiology and a rational basis of therapy. Dig Dis (2015) 33(4):508-14. doi:10.1159/000374099
64. Karaa A, Kamoun WS, Clemens MG. Oxidative stress disrupts nitric oxide synthase activation in liver endothelial cells. Free Radic Biol Med (2005) 39(10):1320-31. doi:10.1016/j.freeradbiomed.2005.06.014
65. Hernandez-Guerra M, Garcia-Pagan JC, Turnes J, Bellot P, Deulofeu R, Abraldes JG, et al. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology (2006) 43(3):485-91. doi:10.1002/hep.21080
66. De Gottardi A, Berzigotti A, Seijo S, D'Amico M, Thormann W, Abraldes JG, et al. Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. Am J Clin Nutr (2012) 96(3):584-90. doi:10.3945/ajcn.112.040469
67. Di Pascoli M, Diví M, Rodríguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, et al. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol (2013) 58(5):904-10. doi:10.1016/j.jhep.2012.12.012
68. Cui L, Jia X, Zhou Q, Zhai X, Zhou Y, Zhu H. Curcumin affects β-catenin pathway in hepatic stellate cell in vitro and in vivo. J Pharm Pharmacol (2014) 66(11):1615-22. doi:10.1111/jphp.12283
69. Sur S, Pal D, Mandal S, Roy A, Panda CK. Tea polyphenols epigallocatechin gallete and theaflavin restrict mouse liver carcinogenesis through modulation of self-renewal Wnt and hedgehog pathways. J Nutr Biochem (2016) 27:32-42. doi:10.1016/j.jnutbio.2015.08.016
70. Pez F, Lopez A, Kim M, Wands JR, Caron De Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol (2013) 59:1107-17. doi:10.1016/j.jhep.2013.07.001
71. Clerbaux L-A, Manco R, Leclercq I. Upstream regulators of hepatic Wnt/β-catenin activity control liver metabolic zonation, development, and regeneration. Hepatology (2016) 64(4):1361-3. doi:10.1002/hep.28763
72. Thompson MD, Monga SPS. WNT/β-catenin signaling in liver health and disease. Hepatology (2007) 45(5):1298-305. doi:10.1002/hep.21651
73. Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One (2016) 11(6):e0158156. doi:10.1371/journal.pone.0158156
74. Sun B, Karin M. NF-KB signaling, liver disease and hepatoprotective agents. Oncogene (2008) 27(48):6228-44. doi:10.1038/onc.2008.300
75. Gracia-Sancho J, Contreras PC, Vila S, Garcia-caldero H, Spada AP, Bosch J. The pan caspase inhibitor Emricasan improves the hepatic microcirculatory dysfunction of CCl4-cirrhotic rats leading to portal hypertension amelioration and cirrhosis regression. Hepatology (2016) 64(S1):811-1050. doi:10.1002/hep.28800
76. Frenette CT, Morelli G, Shiftman ML, Frederick RT, Rubin R, Fallon MB, et al. Emricasan (IDN-6556) orally for 6 months in patients with non-alcoholic steatohepatitis (NASH) cirrhosis decreases the progression of MELD score and improves liver function. Hepatology (2016) 64(S1):811-1050. doi:10.1002/hep.28800
77. Mesquita F, Guixe-Muntet S, Fernandez-Iglesias A, Maeso-Diaz R, Hide D, Ortega-Ribera M, et al. Liraglutide de-activates hepatic stellate cells improving liver microvascular dysfunction and fibrosis in rats with chronic liver disease. Hepatology (2016) 64(S1):1-136. doi:10.1002/hep.28796
78. Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep (2016) 6:33453. doi:10.1038/srep33453
79. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet (2015) 385(9972):956-65. doi:10.1016/S0140-6736(14)61933-4
80. Liu SB, Ikenaga N, Peng Z-W, Sverdlov DY, Greenstein A, Smith V, et al. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. FASEB J (2016) 30(4):1599-609. doi:10.1096/fj.14-268425